AR005281A1 - Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. . - Google Patents
Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. .Info
- Publication number
- AR005281A1 AR005281A1 ARP960105899A ARP960105899A AR005281A1 AR 005281 A1 AR005281 A1 AR 005281A1 AR P960105899 A ARP960105899 A AR P960105899A AR P960105899 A ARP960105899 A AR P960105899A AR 005281 A1 AR005281 A1 AR 005281A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage form
- manufacture
- preparation
- composition
- oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Abstract
Una forma de dosis farmacéutica oral que comprende un inhibidor de bombeo protónico susceptible al ácido con uno o más agentes antiácidos o alginatos yopcionalmente excipientes farmacéuticamente aceptables, que la forma de dosis tiene la formade una forma de dosis unitaria fija que comprende al menos doscomponentes farmacéuticamente activos y donde el inhibidor de bombeo protónico está protegido por una capa de revestimiento entérica. La forma de dosisunitaria múltiple es la máspreferida. La nueva formulación fija es especialmente útil para el tratamiento de los trastornos asociados con ladespepsia como por ejemplo, la acidez. Procedimiento para su preparación y uso de dicha forma en la fabricación de unmedicamento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9600071A SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | New oral formulation of two active ingredients I |
Publications (1)
Publication Number | Publication Date |
---|---|
AR005281A1 true AR005281A1 (es) | 1999-04-28 |
Family
ID=20400969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960105899A AR005281A1 (es) | 1996-01-08 | 1996-12-26 | Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. . |
Country Status (35)
Country | Link |
---|---|
US (1) | US6183776B1 (es) |
EP (1) | EP0813424B2 (es) |
JP (1) | JPH11501950A (es) |
KR (1) | KR100490075B1 (es) |
CN (1) | CN1080125C (es) |
AR (1) | AR005281A1 (es) |
AT (1) | ATE228009T1 (es) |
AU (1) | AU712669B2 (es) |
BR (1) | BR9607350B1 (es) |
CA (1) | CA2213996C (es) |
CZ (1) | CZ293583B6 (es) |
DE (1) | DE69624907T3 (es) |
DK (1) | DK0813424T4 (es) |
EE (1) | EE04002B1 (es) |
EG (1) | EG23821A (es) |
ES (1) | ES2185817T5 (es) |
HK (2) | HK1001763A1 (es) |
HU (1) | HU229153B1 (es) |
IL (1) | IL121651A (es) |
IS (1) | IS2716B (es) |
MX (1) | MX9706785A (es) |
MY (1) | MY116091A (es) |
NO (1) | NO326656B1 (es) |
NZ (1) | NZ325977A (es) |
PL (1) | PL187075B1 (es) |
PT (1) | PT813424E (es) |
RU (1) | RU2179453C2 (es) |
SA (1) | SA97170553B1 (es) |
SE (1) | SE9600071D0 (es) |
SK (1) | SK283695B6 (es) |
TR (1) | TR199700916T1 (es) |
TW (1) | TW464514B (es) |
UA (1) | UA45392C2 (es) |
WO (1) | WO1997025066A1 (es) |
ZA (1) | ZA9610935B (es) |
Families Citing this family (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US20050054682A1 (en) * | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
AU5446798A (en) * | 1996-11-27 | 1998-06-22 | Procter & Gamble Company, The | Compositions and methods for the treatment of gastrointestinal disorders |
MX9703918A (es) * | 1997-05-28 | 1998-11-30 | J Marshall M D Barry | Procedimiento para preparar un producto farmaceutico reactivo para deteccion de desorden gastrointestinal causado por bacteria en el tracto gastrointestinal superior. |
SE510650C2 (sv) * | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
JP2001513570A (ja) * | 1997-08-25 | 2001-09-04 | ザ、プロクター、エンド、ギャンブル、カンパニー | 上部胃腸管不調治療用複合製剤 |
PL195266B1 (pl) * | 1997-12-08 | 2007-08-31 | Altana Pharma Ag | Jednostka związku aktywnego nietrwałego w środowisku kwaśnym, sposób jej otrzymywania, czopki zawierające aktywny związek nietrwały w środowisku kwaśnym oraz sposób ich otrzymywania |
SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
FR2774906B1 (fr) * | 1998-02-13 | 2000-05-12 | Rhodia Chimie Sa | Systeme d'encapsulation a coeur organique et a ecorce minerale a base d'hydroxycarbonate d'aluminium et son procede de preparation |
DK1736144T3 (en) | 1998-05-18 | 2015-12-07 | Takeda Pharmaceutical | Orally disintegrating tablets. |
UA69413C2 (uk) * | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції |
US7122207B2 (en) | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
ATE481090T1 (de) | 1998-07-28 | 2010-10-15 | Takeda Pharmaceutical | Leicht zerfallende feste zubereitung |
SE9803772D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
PL360916A1 (en) * | 1999-03-29 | 2004-09-20 | Wyeth | Coating system |
EP1210091A4 (en) * | 1999-07-12 | 2009-07-29 | Smithkline Beecham Corp | TREATMENT OF STOMACH BREEDERS |
DK1222922T3 (da) | 1999-10-20 | 2007-12-03 | Eisai R&D Man Co Ltd | Fremgangsmåde til stabilisering af benzimidazolforbindelser |
US20040191276A1 (en) * | 1999-11-30 | 2004-09-30 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
US20020064555A1 (en) * | 2000-09-29 | 2002-05-30 | Dan Cullen | Proton pump inhibitor formulation |
US20020192299A1 (en) * | 2000-12-28 | 2002-12-19 | Rajneesh Taneja | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
SE0101379D0 (sv) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
RU2301662C2 (ru) * | 2001-07-16 | 2007-06-27 | Астразенека Аб | Фармацевтический препарат, содержащий ингибитор протонной помпы и антациды |
AR036354A1 (es) * | 2001-08-31 | 2004-09-01 | Takeda Chemical Industries Ltd | Preparacion solida |
CN100408029C (zh) * | 2001-09-28 | 2008-08-06 | 麦克内尔-Ppc股份有限公司 | 有镶嵌部分的组合剂型 |
US9358214B2 (en) * | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US7008777B2 (en) | 2001-10-15 | 2006-03-07 | Barry J. Marshall | System for the detection of urease and method for using same |
CA2472103A1 (en) * | 2002-01-25 | 2003-08-07 | Santarus, Inc. | Transmucosal delivery of proton pump inhibitors |
KR100479637B1 (ko) * | 2002-02-01 | 2005-03-31 | 한국화학연구원 | 란소프라졸을 함유하는 경구제제 및 그의 제조방법 |
CO5400144A1 (es) * | 2002-03-11 | 2004-05-31 | Novartis Ag | Compuestos organicos |
ATE419840T1 (de) | 2002-04-09 | 2009-01-15 | Flamel Tech Sa | Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen |
US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
US20040082618A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
US20040081700A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Dose titratable liquid dosage forms of acid labile drugs |
US6663892B1 (en) * | 2002-08-19 | 2003-12-16 | L. Perrigo Company | Multiple portion tablet |
EP1552833B1 (en) * | 2002-10-16 | 2016-12-28 | Takeda Pharmaceutical Company Limited | Process for producing an amorphous optically active isomer of lansoprazole |
SE0203065D0 (sv) * | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
US9107804B2 (en) | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
US8367111B2 (en) * | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
US7258981B2 (en) * | 2003-01-24 | 2007-08-21 | Clontech Laboratories, Inc. | Sensitive proteasome sensor constructs and methods for their design and use |
US20040166162A1 (en) * | 2003-01-24 | 2004-08-26 | Robert Niecestro | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
CA2517005A1 (en) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
EP1759692A3 (en) * | 2003-03-10 | 2007-09-12 | Novartis AG | Taste-masked solid veterinary compositions |
WO2004082692A1 (ja) * | 2003-03-18 | 2004-09-30 | Kowa Co., Ltd. | 制酸剤組成物 |
US8802139B2 (en) * | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
AR045062A1 (es) * | 2003-07-18 | 2005-10-12 | Santarus Inc | Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas |
US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20050031700A1 (en) * | 2003-07-18 | 2005-02-10 | Sanatarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
WO2005011637A1 (ja) * | 2003-08-04 | 2005-02-10 | Eisai Co., Ltd. | 用時分散型製剤 |
US7252665B2 (en) * | 2003-10-31 | 2007-08-07 | Medtronic, Inc | Ablation of stomach lining to reduce stomach acid secretion |
US7282050B2 (en) * | 2003-10-31 | 2007-10-16 | Medtronic, Inc. | Ablation of exterior of stomach to treat obesity |
US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
US7041124B2 (en) * | 2003-12-23 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | System and method for providing therapy to a portion of a body |
GB0403165D0 (en) * | 2004-02-12 | 2004-03-17 | Ct | Novel uses for proton pump inhibitors |
US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
WO2005123042A1 (en) * | 2004-06-10 | 2005-12-29 | Glatt Air Techniques, Inc. | Controlled release pharmaceutical formulation |
US20050281876A1 (en) * | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
GB2418854B (en) * | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
US8747895B2 (en) * | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) * | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
CA2584957C (en) | 2004-10-21 | 2015-08-25 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
US20060165797A1 (en) * | 2005-01-12 | 2006-07-27 | Pozen Inc. | Dosage form for treating gastrointestinal disorders |
US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
SE530605C2 (sv) * | 2005-09-29 | 2008-07-15 | Barbara Nelson | Läkemedel innehållande ett syrahämmande medel, avseende att användas för att motverka och bota luftvägssjukdomar |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
SG184754A1 (en) * | 2005-12-28 | 2012-10-30 | Takeda Pharmaceutical | Controlled release solid preparation |
CA2648280C (en) * | 2006-04-03 | 2014-03-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
EP2012756A4 (en) * | 2006-04-20 | 2013-01-23 | Inventia Healthcare Private Ltd | MULTI-UNIT COMPOSITIONS |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
JP2009538901A (ja) * | 2006-06-01 | 2009-11-12 | デクセル ファーマ テクノロジーズ エルティーディー. | 複式ユニット製薬的製剤 |
AR056062A1 (es) * | 2006-06-05 | 2007-09-19 | Bago Sa Labor | Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion |
CN101120930B (zh) * | 2006-08-11 | 2010-09-29 | 石药集团中奇制药技术(石家庄)有限公司 | 一种奥美拉唑组合物及其制备方法 |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
WO2008057802A2 (en) | 2006-10-27 | 2008-05-15 | The Curators Of The University Of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
US20080194307A1 (en) * | 2007-02-13 | 2008-08-14 | Jeff Sanger | Sports-based game of chance |
CN101259140B (zh) * | 2007-03-08 | 2012-08-22 | 重庆北碚现代应用药物研究所 | 一种治疗胃炎、胃溃疡及十二指肠溃疡的复方药物及其制备方法 |
US9597293B2 (en) * | 2007-05-07 | 2017-03-21 | Evonik Röhm Gmbh | Solid dosage forms comprising an enteric coating with accelerated drug release |
EP2044929A1 (en) * | 2007-10-04 | 2009-04-08 | Laboratorios del Dr. Esteve S.A. | Oral fast distintegrating tablets |
ITFI20070253A1 (it) * | 2007-11-09 | 2009-05-10 | Valpharma Internat S P A | Formulazioni farmaceutiche per la somministrazione di ipp. |
WO2009105568A1 (en) | 2008-02-20 | 2009-08-27 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
EP2127643A1 (de) * | 2008-05-30 | 2009-12-02 | Bayer Schering Pharma Aktiengesellschaft | Orale Pelletformulierungen mit zeitversetzter Wirkstofffreigabe |
EP2344139A1 (en) | 2008-09-09 | 2011-07-20 | AstraZeneca AB | Method for delivering a pharmaceutical composition to patient in need thereof |
WO2010038241A2 (en) * | 2008-09-30 | 2010-04-08 | Panacea Biotec Limited | Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid |
JP2012072061A (ja) * | 2009-01-29 | 2012-04-12 | Eisai R & D Management Co Ltd | 新規組成物 |
US20110008432A1 (en) * | 2009-06-25 | 2011-01-13 | Pozen Inc. | Method for Treating a Patient in Need of Aspirin Therapy |
EA201290026A1 (ru) | 2009-06-25 | 2012-07-30 | Астразенека Аб | Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) |
WO2011067667A2 (en) | 2009-12-02 | 2011-06-09 | Eurand Pharmaceuticals Limited | Fexofenadine microcapsules and compositions containing them |
WO2011080500A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
US20120294937A1 (en) | 2009-12-29 | 2012-11-22 | Novartis Ag | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
WO2011080502A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
AR079862A1 (es) * | 2010-01-08 | 2012-02-22 | Eurand Inc | Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion |
EA024050B1 (ru) | 2010-04-23 | 2016-08-31 | С-БИОТЕК ХОЛДИНГ АпС | Твердая фармацевтическая композиция для нейтрализации желудочной кислоты |
BR112014016085A8 (pt) | 2011-12-28 | 2017-07-04 | Pozen Inc | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico |
US20140127296A1 (en) * | 2012-11-05 | 2014-05-08 | Kenneth John Tibbs | Pharmaceutical preparation and method for treatment of diabetes |
US20150238514A1 (en) * | 2014-02-21 | 2015-08-27 | William Armstrong | Protective Supplement Configuration |
EP3288556A4 (en) * | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US20190151297A1 (en) * | 2016-04-29 | 2019-05-23 | Nauts Equine Brand Pty Ltd | Veterinary Composition |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
TR201723199A2 (tr) * | 2017-12-30 | 2019-07-22 | Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi | Yeni farmasötik bileşimler. |
KR102080023B1 (ko) | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
KR102006777B1 (ko) * | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제 |
BR112021002796A2 (pt) * | 2018-08-23 | 2021-05-04 | Chong Kun Dang Pharmaceutical Corp. | composição farmacêutica e método para preparar uma composição farmacêutica |
BR112022007223A2 (pt) * | 2019-10-17 | 2022-07-05 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica e formulação de combinação farmacêutica |
MX2022009121A (es) * | 2020-01-23 | 2022-08-18 | Hanmi Pharm Ind Co Ltd | Formulacion farmaceutica compuesta que comprende un inhibidor de la bomba de protones y un antiacido. |
CN114980867B (zh) * | 2020-01-23 | 2024-03-15 | 韩美药品株式会社 | 包含质子泵抑制剂和抗酸剂的药物复合制剂 |
KR102608889B1 (ko) * | 2020-07-14 | 2023-12-04 | 한미약품 주식회사 | 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법 |
KR20220065997A (ko) * | 2020-11-13 | 2022-05-23 | (주)휴온스 | 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법 |
CN114569579B (zh) | 2020-12-02 | 2023-10-31 | 丽珠医药集团股份有限公司 | 肠溶微丸、其制备方法和包含它的制剂 |
KR20230097346A (ko) * | 2021-12-24 | 2023-07-03 | 한미약품 주식회사 | 프로톤 펌프 저해제 및 제산제를 포함하는 경구용 복합정제의 제조방법 및 이에 의해 제조된 경구용 복합정제 |
KR102553713B1 (ko) * | 2022-11-18 | 2023-07-10 | 고덕상 | 미네랄 촉매제를 이용한 양식어류사료 제조방법 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5535031A (en) | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
JPS5598120A (en) | 1979-01-16 | 1980-07-25 | Shin Etsu Chem Co Ltd | Preparation of drug having enteric coating |
FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
US4340582A (en) | 1981-01-15 | 1982-07-20 | Abbott Laboratories | Erythromycin base tablets |
US4377568A (en) | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
JPS5973529A (ja) | 1982-10-12 | 1984-04-25 | Sankyo Co Ltd | 被覆固形製剤の製造法 |
US4525339A (en) | 1982-10-15 | 1985-06-25 | Hoffmann-La Roche Inc. | Enteric coated oral dosage form |
US4518433A (en) | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
GB2132887A (en) | 1982-11-15 | 1984-07-18 | Procter & Gamble | Enteric-coated anti-inflammatory compositions |
US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
EP0153105B1 (en) | 1984-02-10 | 1992-09-09 | Benzon Pharma A/S | Diffusion coated multiple-units dosage form |
US4568560A (en) | 1984-03-16 | 1986-02-04 | Warner-Lambert Company | Encapsulated fragrances and flavors and process therefor |
SE450087B (sv) | 1985-10-11 | 1987-06-09 | Haessle Ab | Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial |
WO1987004077A1 (en) | 1986-01-03 | 1987-07-16 | The University Of Melbourne | Gastro-oesophageal reflux composition |
US5112813A (en) | 1986-03-07 | 1992-05-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Process for the preparation of a viscosity-stable antacid composition |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
DK179687D0 (da) | 1987-04-08 | 1987-04-08 | Farma Food As | Praeparat |
ATE73328T1 (de) † | 1987-05-08 | 1992-03-15 | Smith Kline French Lab | Pharmazeutische zusammensetzungen. |
KR960011236B1 (ko) † | 1987-05-08 | 1996-08-21 | 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 | 제약학적 조성물 및 고체 제형 |
GB8809421D0 (en) | 1988-04-21 | 1988-05-25 | Fordonal Sa | Antacid compositions with prolonged gastric residence time |
AU627775B2 (en) | 1988-09-20 | 1992-09-03 | Glaxo Group Limited | Pharmaceutical compositions |
SE8803822D0 (sv) | 1988-10-26 | 1988-10-26 | Novel dosage form | |
US5026559A (en) † | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
DE4023028A1 (de) * | 1990-07-20 | 1992-01-23 | Hoechst Ag | Ferroelektrische fluessigkristalline si-enthaltende copolymere, ein verfahren zu ihrer herstellung, mischungen dieser copolymere mit niedermolekularen fluessigkristallen und die verwendung in elektrooptischen bauteilen |
US5244670A (en) * | 1991-04-04 | 1993-09-14 | The Procter & Gamble Company | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress |
IT1251153B (it) | 1991-08-06 | 1995-05-04 | Vectorpharma Int | Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica |
JP3142919B2 (ja) | 1991-11-06 | 2001-03-07 | 旭化成株式会社 | セルロース誘導体ラテックス及びその製法 |
US5160742A (en) | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
US5229137A (en) † | 1992-05-06 | 1993-07-20 | Brigham And Women's Hospital, Inc. | Methods and pharmaceutical compositions for treating episodic heartburn |
US5447918A (en) | 1992-07-27 | 1995-09-05 | Mccullough; Ricky W. | Gastrointestinal anti-irritant composition comprising sucralfate and methods of use |
CA2141582C (en) | 1992-08-05 | 2003-09-30 | Angelo Mario Morella | Pelletised pharmaceutical composition |
US5330759A (en) | 1992-08-26 | 1994-07-19 | Sterling Winthrop Inc. | Enteric coated soft capsules and method of preparation thereof |
CA2110313C (en) † | 1992-12-01 | 2004-10-26 | Edward John Roche | Pharmaceutical compositions containing a guanidinothiazole compound and antacids |
AU7218294A (en) † | 1993-07-06 | 1995-02-06 | Mcneil-Ppc, Inc. | H2 antagonist-alginate combinations |
JPH08512321A (ja) | 1993-07-06 | 1996-12-24 | メルク エンド カンパニー インコーポレーテッド | H▲下2▼拮抗剤−アルギネート−制酸剤の組合せ物 |
WO1995008332A1 (en) | 1993-09-20 | 1995-03-30 | The Procter & Gamble Company | Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection |
JP3017906B2 (ja) | 1993-10-08 | 2000-03-13 | 信越化学工業株式会社 | 腸溶性コーティング剤分散液 |
ATE219931T1 (de) | 1993-10-12 | 2002-07-15 | Mitsubishi Pharma Corp | Darmlösliche grannulatkörner enthaltende tablette |
GB2285989A (en) | 1994-01-28 | 1995-08-02 | Merck Frosst Canada Inc | Aqueous formulations for enteric coatings |
AUPM596894A0 (en) | 1994-05-30 | 1994-06-23 | Hybrid Scientific Pty Ltd | Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders |
SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
JP3350054B2 (ja) | 1994-07-08 | 2002-11-25 | アストラゼネカ・アクチエボラーグ | 複数単位の錠剤化された剤形▲i▼ |
AUPM695294A0 (en) | 1994-07-20 | 1994-08-11 | Borody, Thomas Julius | Improved combination therapy dose unit |
WO1996029055A1 (en) | 1995-03-17 | 1996-09-26 | The Boots Company Plc | Pectin liquid pharmaceutical compositions |
US5824339A (en) * | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
AU5446798A (en) | 1996-11-27 | 1998-06-22 | Procter & Gamble Company, The | Compositions and methods for the treatment of gastrointestinal disorders |
-
1996
- 1996-01-08 SE SE9600071A patent/SE9600071D0/xx unknown
- 1996-12-20 RU RU97116726/14A patent/RU2179453C2/ru not_active IP Right Cessation
- 1996-12-20 PL PL96322175A patent/PL187075B1/pl not_active IP Right Cessation
- 1996-12-20 DE DE69624907T patent/DE69624907T3/de not_active Expired - Lifetime
- 1996-12-20 IL IL12165196A patent/IL121651A/xx not_active IP Right Cessation
- 1996-12-20 CZ CZ19972747A patent/CZ293583B6/cs not_active IP Right Cessation
- 1996-12-20 DK DK96944726T patent/DK0813424T4/da active
- 1996-12-20 ES ES96944726T patent/ES2185817T5/es not_active Expired - Lifetime
- 1996-12-20 SK SK1169-97A patent/SK283695B6/sk not_active IP Right Cessation
- 1996-12-20 CN CN96193594A patent/CN1080125C/zh not_active Expired - Fee Related
- 1996-12-20 MX MX9706785A patent/MX9706785A/es not_active IP Right Cessation
- 1996-12-20 AT AT96944726T patent/ATE228009T1/de active
- 1996-12-20 HU HU9904024A patent/HU229153B1/hu not_active IP Right Cessation
- 1996-12-20 TR TR97/00916T patent/TR199700916T1/xx unknown
- 1996-12-20 UA UA97104949A patent/UA45392C2/uk unknown
- 1996-12-20 JP JP9525131A patent/JPH11501950A/ja active Pending
- 1996-12-20 BR BRPI9607350-0A patent/BR9607350B1/pt not_active IP Right Cessation
- 1996-12-20 WO PCT/SE1996/001737 patent/WO1997025066A1/en active IP Right Grant
- 1996-12-20 US US08/750,934 patent/US6183776B1/en not_active Expired - Lifetime
- 1996-12-20 EP EP96944726A patent/EP0813424B2/en not_active Expired - Lifetime
- 1996-12-20 AU AU13241/97A patent/AU712669B2/en not_active Ceased
- 1996-12-20 CA CA002213996A patent/CA2213996C/en not_active Expired - Fee Related
- 1996-12-20 EE EE9700192A patent/EE04002B1/xx not_active IP Right Cessation
- 1996-12-20 KR KR1019970706236A patent/KR100490075B1/ko not_active IP Right Cessation
- 1996-12-20 PT PT96944726T patent/PT813424E/pt unknown
- 1996-12-20 NZ NZ325977A patent/NZ325977A/xx not_active IP Right Cessation
- 1996-12-26 AR ARP960105899A patent/AR005281A1/es not_active Application Discontinuation
- 1996-12-27 TW TW085116139A patent/TW464514B/zh not_active IP Right Cessation
- 1996-12-30 ZA ZA9610935A patent/ZA9610935B/xx unknown
-
1997
- 1997-01-07 EG EG1897A patent/EG23821A/xx active
- 1997-01-07 MY MYPI97000065A patent/MY116091A/en unknown
- 1997-01-15 SA SA97170553A patent/SA97170553B1/ar unknown
- 1997-08-20 IS IS4548A patent/IS2716B/is unknown
- 1997-09-04 NO NO19974071A patent/NO326656B1/no not_active IP Right Cessation
-
1998
- 1998-02-05 HK HK98100847A patent/HK1001763A1/xx not_active IP Right Cessation
- 1998-11-06 HK HK98111792A patent/HK1017992A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR005281A1 (es) | Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. . | |
AR005282A1 (es) | Composición farmacéutica oral en la forma de un comprimido de unidades múltiples, uso de la misma para la preparación de medicamnetos, y procedimiento para su manufactura. | |
ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
SE9600072D0 (sv) | New oral formulation of two active ingredients II | |
SV2004001556A (es) | Preparaciones acidas de insulina con establidad mejorada | |
CO5200837A1 (es) | Vacunas | |
AR020803A1 (es) | Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento | |
CY2562B1 (en) | Pharmaceutical injectable solution of paracetamol and combinations of paracetamol with other active substances | |
CO5011096A1 (es) | Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs | |
AR018410A1 (es) | Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron | |
MX9200992A (es) | Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion. | |
AR034900A1 (es) | Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica | |
ES2179190T3 (es) | Inhalador dosificador para propianato de fluticasona. | |
AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
UY27296A1 (es) | Composición farmacéutica que contiene mosaprida y pancreatina | |
AR018582A1 (es) | Forma de dosificacion en tableta para administrar un antagonista de los receptores de los leucotrienos y su uso en la preparacion de medicamentos | |
AR018862A1 (es) | Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion | |
ATE333896T1 (de) | Vaskularisierungsinhibitoren | |
BR0210489A (pt) | Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente | |
AR034813A1 (es) | Composiciones farmaceuticas y uso de las mismas | |
UY25798A1 (es) | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. | |
AR026254A1 (es) | El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4 | |
AR014082A1 (es) | Concentrado oral de sertralina | |
AR014881A1 (es) | Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprendedicho sensibilizador y dicho agente | |
AR012996A1 (es) | Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |